US Food and Drug Administration officials are changing the agency's standards for updated COVID-19 booster shots with focus ...

The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from ...

The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

WEDNESDAY May 21, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has decided that only seniors and ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director ...

The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...

The Trump administration said it will limit approval for seasonal COVID-19 shots to seniors and others at high risk pending ...